Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Join ADVENT for an educational symposium on PN at WCI 2025!

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.
ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.